Cargando…
The probability of cost-effectiveness
BACKGROUND: The study of cost-effectiveness comparisons between competing medical interventions has led to a variety of proposals for quantifying cost-effectiveness. The differences between the various approaches can be subtle, and one purpose of this article is to clarify some important distinction...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC100784/ https://www.ncbi.nlm.nih.gov/pubmed/11914138 http://dx.doi.org/10.1186/1471-2288-2-5 |
_version_ | 1782120195932815360 |
---|---|
author | O'Hagan, Anthony Stevens, John W |
author_facet | O'Hagan, Anthony Stevens, John W |
author_sort | O'Hagan, Anthony |
collection | PubMed |
description | BACKGROUND: The study of cost-effectiveness comparisons between competing medical interventions has led to a variety of proposals for quantifying cost-effectiveness. The differences between the various approaches can be subtle, and one purpose of this article is to clarify some important distinctions. DISCUSSION: We discuss alternative measures in the framework of individual, patient-level, incremental net benefits. In particular we examine the probability of cost-effectiveness for an individual, proposed by Willan. SUMMARY: We argue that this is a useful addition to the range of cost-effectiveness measures, but will be of secondary interest to most decision makers. We also demonstrate that Willan's proposed estimate of this probability is logically flawed. |
format | Text |
id | pubmed-100784 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2002 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-1007842002-04-04 The probability of cost-effectiveness O'Hagan, Anthony Stevens, John W BMC Med Res Methodol Debate BACKGROUND: The study of cost-effectiveness comparisons between competing medical interventions has led to a variety of proposals for quantifying cost-effectiveness. The differences between the various approaches can be subtle, and one purpose of this article is to clarify some important distinctions. DISCUSSION: We discuss alternative measures in the framework of individual, patient-level, incremental net benefits. In particular we examine the probability of cost-effectiveness for an individual, proposed by Willan. SUMMARY: We argue that this is a useful addition to the range of cost-effectiveness measures, but will be of secondary interest to most decision makers. We also demonstrate that Willan's proposed estimate of this probability is logically flawed. BioMed Central 2002-03-11 /pmc/articles/PMC100784/ /pubmed/11914138 http://dx.doi.org/10.1186/1471-2288-2-5 Text en Copyright © 2002 O'Hagan and Stevens; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL. |
spellingShingle | Debate O'Hagan, Anthony Stevens, John W The probability of cost-effectiveness |
title | The probability of cost-effectiveness |
title_full | The probability of cost-effectiveness |
title_fullStr | The probability of cost-effectiveness |
title_full_unstemmed | The probability of cost-effectiveness |
title_short | The probability of cost-effectiveness |
title_sort | probability of cost-effectiveness |
topic | Debate |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC100784/ https://www.ncbi.nlm.nih.gov/pubmed/11914138 http://dx.doi.org/10.1186/1471-2288-2-5 |
work_keys_str_mv | AT ohagananthony theprobabilityofcosteffectiveness AT stevensjohnw theprobabilityofcosteffectiveness AT ohagananthony probabilityofcosteffectiveness AT stevensjohnw probabilityofcosteffectiveness |